.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
US Army
Express Scripts
AstraZeneca
Covington
Federal Trade Commission
Medtronic
Baxter
Deloitte
Mallinckrodt

Generated: September 22, 2017

DrugPatentWatch Database Preview

Fulvestrant - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fulvestrant and what is the scope of fulvestrant patent protection?

Fulvestrant
is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fulvestrant has sixty-seven patent family members in forty countries.

There are ten drug master file entries for fulvestrant. One supplier is listed for this compound.

Summary for Generic Name: fulvestrant

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list10
Suppliers / Packagers: see list1
Bulk Api Vendors: see list54
Clinical Trials: see list196
Patent Applications: see list7,570
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:fulvestrant at DailyMed

Pharmacology for Ingredient: fulvestrant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fulvestrant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fulvestrant

Country Document Number Estimated Expiration
Japan2011190275► Subscribe
United Kingdom2359254► Subscribe
European Patent Office1250138► Subscribe
Switzerland696260► Subscribe
Israel150230► Subscribe
United Kingdom0000313► Subscribe
Slovakia287221► Subscribe
Norway20150741► Subscribe
Belgium1013477► Subscribe
Czech Republic20022384► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FULVESTRANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/009United Kingdom► SubscribePRODUCT NAME: FULVESTRANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/03/269/001 20040310
04C/004Belgium► SubscribePRODUCT NAME: FULVESTRANT; REGISTRATION NO/DATE: EU/1/03/269/001 20040311
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
Chinese Patent Office
Express Scripts
Medtronic
Healthtrust
Colorcon
Covington
Novartis
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot